The Watchman device is a small, parachute-shaped implant designed to occlude the left atrial appendage (LAA), a structure in the left atrium of the heart where blood clots commonly form in people with atrial fibrillation (AFib). This device reduces the risk of stroke by preventing clots from escaping the LAA and entering the bloodstream.

Benefits Compared to Anticoagulation

1. Stroke Risk Reduction Without Long-Term Anticoagulation:
   
   
   • The Watchman device offers an alternative to long-term anticoagulation (e.g., warfarin, DOACs like Eliquis, Xarelto and Pradaxa), particularly for patients at high risk of bleeding.
2. Lower Bleeding Risk:
   
   
   • Patients can avoid complications associated with chronic anticoagulant use, such as gastrointestinal bleeding or hemorrhagic stroke.
3. Improved Quality of Life:
   
   
   • Eliminates the need for frequent blood tests (e.g., INR monitoring with warfarin) and dietary restrictions.
4. Comparable Efficacy:
   
   
   • Clinical trials (e.g., PROTECT AF and PREVAIL) have shown the device to be non-inferior to warfarin for preventing stroke, systemic embolism, and cardiovascular death.

Candidates for the Watchman Device

Ideal candidates are:

• Patients with non-valvular atrial fibrillation (AFib not caused by valve disease) who have:
  • A high stroke risk (CHA2DS2-VASc score ≥ 3).
  • Contraindications or high risk of bleeding with long-term anticoagulation therapy.
  • History of bleeding complications from anticoagulants.
  • Difficulty maintaining therapeutic INR levels or intolerance to direct oral anticoagulants.

Patients should have no contraindications to short-term anticoagulation (e.g., during the post-implantation period).

Potential Complications

1. Periprocedural Risks:
   
   
   • Pericardial effusion or tamponade.
   • Device embolization.
   • Vascular complications at the catheter insertion site.
   • Stroke during the procedure.
2. Long-Term Risks:
   
   
   • Device-related thrombus formation.
   • Incomplete LAA closure, leaving residual stroke risk.
   • Infection at the device site (rare).
3. Other Risks:
   
   
   • Procedural anesthesia risks and rare cases of atrial perforation.

Anticoagulation Required After the Watchman

• Following implantation, most protocols recommend:
  1. 45 days of anticoagulation (commonly warfarin or a direct oral anticoagulant) along with aspirin.
  2. After 45 days, a follow-up transesophageal echocardiogram (TEE) assesses for device seal and thrombus. If satisfactory, anticoagulation may transition to dual antiplatelet therapy (aspirin and clopidogrel) for 6 months.
  3. After 6 months, therapy is typically reduced to lifelong aspirin.

Follow-Up Monitoring After the Watchman

1. Initial Follow-Up:
   
   
   • Transesophageal echocardiogram (TEE) at approximately 45 days post-implantation to check for:
     • Proper device positioning.
     • LAA seal.
     • Absence of thrombus on the device.
2. Long-Term Monitoring:
   
   
   • Regular clinical evaluations to assess for stroke symptoms, bleeding risks, and arrhythmia control.
   • Routine imaging or TEE as needed based on symptoms or complications.
3. Lifelong Risk Management:
   
   
   • Continued antiplatelet therapy and management of comorbidities such as hypertension, diabetes, and dyslipidemia to minimize cardiovascular risk.

The Watchman device is a promising alternative for stroke prevention in select patients, but careful patient selection, skilled procedural execution, and diligent follow-up are essential to its success.

WOLFSON Note: I have rarely recommended this device. There are many natural remedies to prevent a stroke in people with AFIB. 

Please read my other blogs about natural blood thinners and AFIB strategies including my online AFIB course here.